Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Inolimomab

EU orphan designation number: EU/3/01/028   
Active ingredient: Inolimomab
Indication: Treatment of Graft versus Host Disease
Sponsor: EUSA Pharma SAS
3 Allée des Séquoias, F-69760 Limonest, France

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
08/03/2001 Centralised Orphan - Designation EMEA/OD/038/00 (2001)488 of 05/03/2001
20/07/2004 Other procedure
22/01/2008 Other procedure